Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: Less cost at the expense of more genitourinary toxicity is a concerning but testable hypothesis

Journal of Clinical Oncology

Volumn 32, Issue 12, 2014, Pages 1183-1185

  D'Amico, Anthony V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER REGISTRY; CANCER SCREENING; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; CYSTOSCOPY; EDITORIAL; FOLLOW UP; HEALTH CARE QUALITY; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; LIFE EXPECTANCY; MALE; NEEDLE BIOPSY; NEPHROTOXICITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEREOTACTIC BODY RADIATION THERAPY; URETHRA STRICTURE; URINARY TRACT OBSTRUCTION; URINE INCONTINENCE; UROFLOWMETRY; UROGENITAL TRACT TOXICITY; NOTE; PROSTATE TUMOR;

HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84904737897     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.2380     Document Type: Editorial

References (24)

1. Schröder FH, Hugosson J, Roobol MJ, et al: Screening and prostatecancer mortality in a randomized European study. N Engl J Med 360:1320-1328, 2009
2. Hugosson J, Carlsson S, Aus G, et al: Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11:725-732, 2010
3. Crawford ED, Grubb R 3rd, Black A, et al: Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol 29:355-361, 2010
4. US Preventative Services Task Force: Screening for prostate cancer: Current recommendation. 2012. http://www.uspreventiveservicestaskforce.org/ prostatecancerscreening.htm
5. Wilt TJ, Brawer MK, Jones KM, et al: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203-213, 2012
6. Mohler JL, Kantoff PW, Armstrong AJ, et al: Prostate cancer, version 1.2014. J Natl Compr Canc Netw 11:1471-1479, 2013
7. Andriole GL, Crawford ED, Grubb RL 3rd, et al: Mortality results from randomized prostate-cancer screening trial. N Engl J Med 360:1310-1319, 2009
8. Aizer AA, Chen MH, Hattangadi J, D'Amico AV: Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer. BJU Int 113:43-50, 2014
9. US Social Security Administration: Actuarial life table. http://www.ssa.gov/oact/STATS/table4c6.html
10. Esserman LJ, Thompson IM Jr, Reid B: Overdiagnosis and overtreatment in cancer: An opportunity for improvement. JAMA 310:797-798, 2013
11. Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion: Prostate cancer rates by race and ethnicity. 2013. http://www.cdc.gov/cancer/prostate/statistics/race.htm
12. Suardi N, Briganti A, Gallina A, et al: Testing the most stringent criteria for selection of candidates for active surveillance in patients with low-risk prostate cancer. BJU Int 105:1548-1552, 2010
13. Ahmed HU, Hindley RG, Dickinson L, et al: Focal therapy for localised unifocal and multifocal prostate cancer: A prospective development study. Lancet Oncol 13:622-632, 2012
14. Boike TB, Lotan Y, Cho LC, et al: Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 29:2020-2026, 2011
15. Cho LC, Timmerman R, Kavanagh B: Hypofractionated external-beam radiotherapy for prostate cancer. Prostate Cancer doi: 10.1155/2013/103547. [epub ahead of print on March 7, 2013]
16. ISRCTN: Phase III study of hypofractionated radiotherapy of intermediate risk localized prostate cancer. http://www.controlled-trials.com/ISRCTN45905321
17. Yu JB, Cramer LD, Herrin J, et al: Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: Comparison of toxicity. J Clin Oncol 32:1195-1202, 2014
18. Rubin DB: Bias reduction using mahalanobis-metric matching. Biometrics 36:293-298, 1980
19. SAS Institute: The MCMC procedure. 2014. http://support.sas.com/ documentation/cdl/en/statug/63962/HTML/default/viewer.htm#statug-mcmc-sect054. htm
20. Resnick MJ, Koyama K, Fan K, et al: Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 368:436-445
21. Cella L, D'Avino V, Liuzzi R, et al: Multivariate normal tissue complication probability modeling of gastrointestinal toxicity after external beam radiotherapy for localized prostate cancer. Radiat Oncol 8:221, 2013
22. Benedict SH, Yenice KM, Followill D, et al: Stereotactic body radiation therapy: The report of AAPM Task Group 101. Med Phys 37:4078-4101, 2010
23. Budäus L, Bolla M, Bossi A, et al: Functional outcomes and complications following radiation therapy for prostate cancer: A critical analysis of the literature. Eur Urol 61:112-127, 2012
24. Sveistrup J, Af Rosenschöld PM, Deasy JO, et al: Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensitymodulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiat Oncol 9:44, 2014